Apparently PKCβ2 does not possess sequence alterations that lead to enzastaurin hypersensitivity. The phosphorylation inhibition of PKCβ2, GSK3β, S6RP, Akt, and FKHR may constitute a useful pharmacodynamic parameter for in vivo target inhibition by enzastaurin.
Sang-Haak Lee and Tingan Chen contributed equally to this work.
This work was supported in part by grants U01-CA101222 and P50-CA119997 to G. B. from the National Cancer Institute.
Clin Lung Cancer. 2010;11(3) © 2010 CIG Media Group, LP
Cite this: Protein Kinase C-β Gene Variants, Pathway Activation, and Enzastaurin Activity in Lung Cancer - Medscape - May 01, 2010.